Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Nutriband Inc WT (NQ: NTRBW )

1.500 UNCHANGED
Last Price Updated: 3:56 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nutriband Inc WT

< Previous 1 2 3 4 Next >
Nutriband Receives Hong Kong Patent Notice of Publication for Its Aversa™ Abuse Deterrent Transdermal Technology
AVERSA Fentanyl has the potential to be the world's first and only abuse-deterrent opioid patch 
From Nutriband Inc.
Via GlobeNewswire
Nutriband Inc. Issued Full Patent from the Chinese National Intellectual Property Administrant for Its "Abuse and Misuse Deterrent Transdermal System" Application
Via ACCESSWIRE
Nutriband Inc Mosquito Repellent Patch Approved by Ministry of Health of Costa Rica
Via ACCESSWIRE
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on October 17
Via ACCESSWIRE
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors
Via ACCESSWIRE
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
From FN Media Group LLC
Via GlobeNewswire
NUTRIBAND RECEIVES CHINA PATENT NOTICE OF ALLOWANCE FOR ITS AVERSA™ ABUSE DETERRENT TRANSDERMAL TECHNOLOGY
Notice of Allowance received from Chinese National Intellectual Property Administration (CNIPA) for a patent application covering its Nutriband AVERSA™ abuse deterrent transdermal technology Nutriband... 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Nutriband Receives China Patent Notice of Allowance for Its Aversa(TM) Abuse Deterrent Transdermal Technology
Via ACCESSWIRE
Nutriband Inc. Announces $8.4M Private Placement
Via ACCESSWIRE
Nutriband Inc. to Present at The Microcap Conference Atlantic City January 30th through February 1st
Via ACCESSWIRE
Nutriband Licenses Bitrex(R) Brand Aversive Agent for Its Lead Product - Aversa(TM) Fentanyl Transdermal Patch
Via ACCESSWIRE
Nutriband Inc. Authorizes $1M Share Buyback Program
Via ACCESSWIRE
Nutriband Inc. Quarterly Report Highlights Strong Cash Position, and Strategic Progress Toward NDA Filing for AVERSA Fentanyl in 2025
Via ACCESSWIRE
Join Nutriband's Exclusive Live Investor Webinar and Q&A Session on July 25
Via ACCESSWIRE
Nutriband Receives Notice of Allowance for U.S. Trademark Covering AVERSA(TM) Abuse Deterrent Technology
Via ACCESSWIRE
Nutriband Provides Product Development Update for Its Lead Product Aversa Fentanyl
Via ACCESSWIRE
Nutriband Inc. Quarterly Report Emphasizes Focus on Kinesiology Tape Output as Q1 Sports Tape Revenues Increase 219% Year Over Year
Via ACCESSWIRE
Nutriband Closes $8.4M Private Placement for Commercial Development of Aversa(R) Fentanyl Transdermal Patch Through FDA Submission
Via ACCESSWIRE
Nutriband Inc. Signs Exclusive Supplier Agreement with Major Sports Brand Licensee Fit for Life Group
Via ACCESSWIRE
Nutriband Inc. Begins Manufacturing for Major Sports Brand Licensee Fit for Life Group, Whose Collection of Partnered Brands Include Reebok, Adidas and New Balance
Via ACCESSWIRE
Nutriband Provides Clinical and Regulatory Path Overview for Lead Product - AVERSA(R) Fentanyl Transdermal Patch
Via ACCESSWIRE
Nutriband Announces Data Supporting Need for Safer Abuse-Deterrent Transdermal Patches Presented at 2024 American Academy of Pain Medicine Annual Meeting
Via ACCESSWIRE
Prescription Transdermal Patch Abuse and Accidental Pediatric Exposure Remains a Serious Problem in the United States - Surveillance Data to Be Presented at 2024 American Academy of Pain Medicine Annual Meeting
Via ACCESSWIRE
Nutriband CEO Publishes Letter to Shareholders
Via ACCESSWIRE
Nutriband Signs Commercial Development and Clinical Supply Agreement With Kindeva Drug Delivery for Aversa(TM) Fentanyl, an Abuse Deterrent Fentanyl Patch
Via ACCESSWIRE
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling
Via ACCESSWIRE
Nutriband Inc. Signs Supplier Agreement With KT Tape, the World Leader in Kinesiology Tape
Via ACCESSWIRE
Nutriband’s Aversa(TM) Buprenoprhine May Reach Peak Annual Sales 0f $70-130 Million Based on Market Assessment by Leading Healthcare Consulting Firm
Via ACCESSWIRE
Nutriband’s Innovative Patent Breaks New Ground in Transdermal Medications
Via Get News
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.